Skip to main content

Table 3 Factors associated with anxiety during an antiviral treatment for hepatitis C virus (HCV) infection at week 12 and at week 24

From: Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C

Characteristics

Week 12

Week 24

β (95% CI)

Wald χ2

p-value

β (95% CI)

Wald χ2

p-value

Treatment group (Group 1 vs. Group 2)

1.07 (0.45–2.56)

0.021

0.884

0.88 (0.38–2.02)

0.088

0.767

Sex (female vs. male)

0.89 (0.34–2.35)

0.055

0.815

0.90 (0.38–2.14)

0.059

0.808

Age at recruitment (year)

0.97 (0.94–1.01)

1.911

0.167

0.98 (0.94–1.01)

1.899

0.168

Body weight (kg)

0.99 (0.95–1.02)

0.624

0.430

0.99 (0.95–1.03)

0.326

0.568

Alcohol use disorder

2.07 (0.58–7.42)

1.235

0.266

1.48 (0.46–4.78)

0.430

0.512

Number of physical comorbidities

1.28 (1.01–1.62)

4.303

0.038*

1.21 (0.96–1.53)

2.581

0.108

α-fetoprotein level (ng/mL)

1.00 (0.99–1.02)

0.123

0.726

0.98 (0.94–1.01)

2.403

0.121

Genotype of HCV (non- 1 vs. 1)

0.66 (0.27–1.63)

0.801

0.371

0.70 (0.28–1.72)

0.615

0.433

Ribavirin daily dose (g/day)

1.20 (0.24–6.00)

0.052

0.820

1.95 (0.67–5.64)

1.505

0.220

Poor treatment response (HCV RNA positive)

1.45 (0.60–3.50)

0.669

0.414

1.53 (0.61–3.82)

0.832

0.362

  1. Note: Group 1, patients who were treated with PegIFN-α-2a plus ribavirin; Group 2, patients who were treated with PegIFN-α-2b plus ribavirin; Anxiety, HADS anxiety score ≥ 8; 95% CI, 95% confidence interval
  2. *p < 0.05